{"id":27933,"date":"2021-11-14T09:36:33","date_gmt":"2021-11-14T08:36:33","guid":{"rendered":"https:\/\/www.transgene.com\/?p=27933"},"modified":"2021-11-22T10:12:24","modified_gmt":"2021-11-22T09:12:24","slug":"annonce-substitut","status":"publish","type":"post","link":"https:\/\/www.transgene.com\/fr\/annonce-substitut\/","title":{"rendered":"annonce substitut"},"content":{"rendered":"\n<div class=\"wp-block-columns eplus-Mq435k cgProduct is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column eplus-cu1f6x is-layout-flow wp-block-column-is-layout-flow\">\n<h3 class=\"cgDeg\">Immunoth\u00e9rapie particuli\u00e8rement innovante, TG4050 est le premier candidat issu de la plateforme <em>myvac<\/em>\u00ae. Ce traitement individualis\u00e9 est bas\u00e9 sur les mutations sp\u00e9cifiques identifi\u00e9es dans la tumeur du patient.<\/h3>\n<p><a class=\"btnVideo cgProductVideo\" title=\"\" href=\"https:\/\/vimeo.com\/481155014?width=640&amp;height=480\" rel=\"wp-video-lightbox\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone  wp-image-27522\" src=\"..\/..\/..\/wp-content\/uploads\/btn-video.svg\" alt=\"\" width=\"101\" height=\"63\" \/> D\u00e9couvrir TG4050 <\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column eplus-33oHGo is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full eplus-YPnM8s\"><img decoding=\"async\" class=\"wp-image-27869\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/process.svg\" alt=\"\" \/><\/figure>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Immunoth\u00e9rapie particuli\u00e8rement innovante, TG4050 est le premier candidat issu de la plateforme myvac\u00ae. Ce traitement individualis\u00e9 est bas\u00e9 sur les mutations sp\u00e9cifiques identifi\u00e9es dans la tumeur du patient. D\u00e9couvrir TG4050<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_uag_custom_page_level_css":"","footnotes":""},"categories":[110],"tags":[],"class_list":["post-27933","post","type-post","status-publish","format-standard","hentry","category-outils-produits","entry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false},"uagb_author_info":{"display_name":"alcyon","author_link":"https:\/\/www.transgene.com\/fr\/author\/alcyon\/"},"uagb_comment_info":0,"uagb_excerpt":"Immunoth\u00e9rapie particuli\u00e8rement innovante, TG4050 est le premier candidat issu de la plateforme myvac\u00ae. Ce traitement individualis\u00e9 est bas\u00e9 sur les mutations sp\u00e9cifiques identifi\u00e9es dans la tumeur du patient. D\u00e9couvrir TG4050","_links":{"self":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/27933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/comments?post=27933"}],"version-history":[{"count":0,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/27933\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/media?parent=27933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/categories?post=27933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/tags?post=27933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}